Invivyd Selects VBY329 as Potential Best-In-Class RSV Antibody Candidate.
ByAinvest
Monday, Nov 24, 2025 11:20 am ET1min read
IVVD--
Invivyd announces the selection of potential best-in-class RSV antibody candidate VBY329, targeting IND readiness in 2H 2026. VBY329 is designed to prevent RSV infections in newborns, infants, and children, and has shown higher potency and improved barrier to resistance compared to standard of care RSV medicines. Its antiviral potency is 1.5-fold greater on average than nirsevimab and 1.2-fold greater on average than clesrovimab against established authentic RSV strains.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet